Targeting of glycoprotein therapeutics

Details Targeting of glycoprotein therapeutics Targeting of glycoprotein therapeutics

2008-03-11

2008-03-11

Prouty, Rebecca E. (Department: 1652)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Stabilized enzymes or enzymes complexed with nonenzyme

C424S094100, C514S008100, C435S208000, C435S188500

Reexamination Certificate

active

07341720

ABSTRACT:
Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.

REFERENCES:
patent: 4701521 (1987-10-01), Ryser et al.
patent: 4749570 (1988-06-01), Poznansky
patent: 5206370 (1993-04-01), Schwartz et al.
patent: 5420285 (1995-05-01), Schwartz et al.
patent: 5521290 (1996-05-01), Sivam et al.
patent: 5753520 (1998-05-01), Schwartz et al.
patent: 5769778 (1998-06-01), Abrams et al.
patent: 5863990 (1999-01-01), Papisov
patent: 6399575 (2002-06-01), Smith et al.
patent: 6562316 (2003-05-01), Edwards et al.
patent: 6569451 (2003-05-01), Li et al.
patent: 6676963 (2004-01-01), Lanza et al.
patent: 6703488 (2004-03-01), Burton et al.
patent: 6749865 (2004-06-01), Calias et al.
patent: 6800273 (2004-10-01), Rajopadhye et al.
patent: 2002/0137125 (2002-09-01), Zhu
patent: 2003/0082176 (2003-05-01), LeBowitz et al.
patent: 2004/0132640 (2004-07-01), DeFrees et al.
patent: 2005/0169968 (2005-08-01), Elmaleh et al.
patent: 2005/0281805 (2005-12-01), LeBowitz et al.
patent: 2006/0051317 (2006-03-01), Batrakova et al.
patent: 384 769 (1990-08-01), None
patent: WO 92/16555 (1992-10-01), None
patent: WO 01/60412 (2001-08-01), None
patent: WO 01/60412 (2001-08-01), None
patent: WO 01/90139 (2001-11-01), None
patent: WO 02/07671 (2002-01-01), None
patent: WO 02/057445 (2002-07-01), None
patent: WO 03/005719 (2003-07-01), None
patent: WO 03/057179 (2003-07-01), None
patent: WO 2005/002515 (2005-01-01), None
patent: WO 2005/077093 (2005-08-01), None
Gregoriadis et al., Polysialic acids: potential in drug delivery. FEBS, 1993, vol. 315 (3): 271-276.
Abraham et al., Heparin-Binding EGF-Like Growth Factor: Characterization of Rat and Mouse CDNA Clones, Protein Domain Conservation Across Species, and Transcript Expression in Tissues,Biochem. Biophys. Res. Commun., 190-125-133, 1993.
Casares et al., Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II-peptide chimera,Nature Biotechnol., 19:142-147, 2001.
Cavallaro et al., Glycosilated Macromolecular Conjugates of Antiviral Drugs with a Polyaspartamide,J. Drug Targeting, 12:593-605, 2004.
Day et al., Induction of Antigen-Specific CTL Responses Using Antigens Conjugated to Short Peptide Vectors,J. Immunol., 170:1498-1503, 2003.
Demeule et al., High Transcytosis of melanotransferrin (P97) across the blood-brain barrier,J. Neurochem., 83:924-933, 2002.
Derossi et al., Trojan peptides: the penetratin system for intracellular delivery,Trends Cell Biol., 8:84-87, 1998.
Dubowchik et al., Cathespin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity,Bioconjugate Chem., 13:855-869, 2002.
Duncan et al., A New Reagent Which May Be Used to Introduce Sulfhydryl Groups into Proteins, and Its Use in the Preparation of Conjugates for Immunoassay,Anal. Biochem., 132:68-73, 1983.
Elliott et al., Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,Cell, 88:223-233, 1997.
Etrych et al., New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties,J. Controlled Release, 73:89-102, 2001.
Fawell et al., Tat mediated delivery of heterologous proteins into cells,Proc. Natl. Acad. Sci. U.S.A., 91:664-668, 1994.
Freireich et al., Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamsetr, Dog, Monkey, and Man,Cancer Chemother. Rep., 50:219-244, 1966.
Friden et al., Characterization, Receptor Mapping and Blood-Brain Barrier Transcytosis of Antibodies to the Human Transferrin Receptor,J. Pharmacol. Exp. Ther., 278:1491-1498, 1996.
Funhoff et al., PEG shielded polymeric double-layered micelles for gene delivery,J. Controlled Release, 102:711-724, 2005.
Furbish et al., Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation,Biochim. Biophys. Acta, 673:425-434, 1981.
Gaillard et al., Targeted delivery across the blood-brain barrier,Expert Opin. Drug Deliv., 2:299-309, 2005.
Geoghegan et al., Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2-Amino Alcohol. Application to Modification at N-Terminal Serine,Bioconjugate Chem., 3:138-146, 1992.
Hamann et al., An Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker,Bioconjugate Chem., 13:40-46, 2002.
Hembrough et al., Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity,Blood, 103:3374-3380, 2004.
Hinman et al., Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics,Cancer Res., 53:3336-3342, 1993.
Horinouchi et al., Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease,Nat. Genet., 10:288-293, 1995.
Jeyakumar et al., Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis,Neuropath. Appl. Neurobiol., 28:343-357, 2002.
Kamada et al., Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting,Nat. Biotechnol., 21:399-404, 2003.
Kaneko et al., New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates-a Correlation between Acid Stability and Cytotoxicity,Bioconjugate Chem., 2:133-141, 1991.
King et al., Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates,Bioconjugate Chem., 10:279-288, 1999.
Kolonin et al., Reversal of obesity by targeted ablation of adipose tissue,Nature Med., 10:625-632, 2004.
Lanciotti et al., Targeting Adenoviral Vectors Using Heterofunctional Polyethylene Glycol FGF2 Conjugates,Mol. Ther., 8:99-107, 2003.
Lebowitz et al., Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice,Proc. Natl. Acad. Sci. U.S.A., 101:3083-3088, 2004.
Lecolley et al., A new approach to bioconjugates for proteins and peptides (“pegylation”) using living radical polymerisation,Chem. Commun., 18:2026-2027, 2004.
Lee et al., Receptor mediated uptake of peptides that bind the human transferrin receptor,Eur. J. Biochem., 268:2004-2012, 2001.
Lisi et al., Polyethylene Glycol:β-Glucuronidase Conjugates as Potential Therapeutic Agents in Acid Mucopolysaccharidosis,J. Appl. Biochem., 4:19-33, 1982.
Mann et al., Endocytosis and targeting of exogenous HIV-1 Tat protein,EMBO J., 10:1733-1739, 1991.
Marshall et al., Demonstration of Feasibility of In Vivo Gene Therapy for Gaucher Disease Using a Chemically Induced Mouse Model,Mol. Ther., 6(2):179-189, 2002.
Mayes et al., Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease,Clin. Chim. Acta., 112:247-251, 1981.
Mceachern et al., AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease,J. Gene Med., 8:719-729, 2006.
Mitchell et al., Polyarginine enters cells more efficiently than other polycationic homopolymers,J. Peptide Res., 56:318-325, 2000.
Mizukami et al., Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage,J. Clin. Invest., 109:1215-1221, 2002.
Munier-Lehmann et al., Re-expression of the Mannose 6-Phosphate R

Affiliated with

Also associated with

Rating

Targeting of glycoprotein therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting of glycoprotein therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting of glycoprotein therapeutics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2807302